Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02792114 · ClinicalTrials.gov registry record · Phase 1
T-Cell Therapy for Advanced Breast Cancer
A Phase 1 study of Breast Cancer and Metastatic HER2-negative Breast, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 186
- Enrollment target
- 7
- Study locations
NCT02792114 is a Phase 1 study of Breast Cancer and Metastatic HER2-negative Breast that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 186 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT02792114, a Phase 1 study of Breast Cancer and Metastatic HER2-negative Breast, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 186 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to test the safety of different doses of specially prepared T cells collected from the blood. The investigators want to find a safe dose of these modified T cells for patients who have metastatic HER2-negative breast cancer.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG AP1903
- BIOLOGICAL Mesothelin-targeted T cells
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center at Commack (Consent and follow-up only) - Commack
- Memorial Sloan Kettering Westchester (Consent and follow-up only) - East White Plains
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Consent and Follow-Up only) - Uniondale
New Jersey
- Memorial Sloan Kettering Cancer Center (Consent and follow-up only) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent and follow-up only) - Middletown
- Memorial Sloan Kettering Bergen (Consent and follow-up only) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2016-06 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02792114
The ClinicalTrials.gov registry entry for NCT02792114 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT02792114 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02792114 about?
NCT02792114 is a clinical study titled "T-Cell Therapy for Advanced Breast Cancer". The purpose of this study is to test the safety of different doses of specially prepared T cells collected from the blood. The investigators want to find a safe dose of these modified T cells for patients who have metastatic HER2-negative breast cancer.
What is the current status of trial NCT02792114?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 186 participants. The study started on 2016-06. Estimated completion is 2026-06.
What conditions does trial NCT02792114 study?
This clinical trial studies the following conditions: Breast Cancer, Metastatic HER2-negative Breast.
What interventions are being tested in trial NCT02792114?
The interventions under investigation include: Cyclophosphamide (DRUG), AP1903 (DRUG), Mesothelin-targeted T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02792114?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02792114 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.